Skip to main content
BIOME AUSTRALIA LIMITED logo

BIOME AUSTRALIA LIMITED — Investor Relations & Filings

Ticker · BIO ISIN · AU0000184137 ASX Manufacturing
Open in API
Filings indexed 303 across all filing types
Latest filing 2026-02-01 Regulatory Filings
Country AU Australia
Listing ASX BIO

About BIOME AUSTRALIA LIMITED

https://www.biomeaustralia.com

Biome Australia Limited is a microbiome health company specializing in the development and distribution of evidence-based probiotics and complementary medicines. The company focuses on translating microbiome science into accessible healthcare solutions through its flagship brand, Activated Probiotics. Its product portfolio consists of condition-specific formulations designed to address various health areas, including digestive health, immune system support, bone density, and mental wellbeing via psychobiotics. Biome Australia prioritizes clinical research and collaborates with global experts to ensure the efficacy of its formulations. The company’s distribution strategy centers on a network of community pharmacies and independent health practitioners, providing professional-grade supplements to the retail and clinical markets.

Recent filings

Filing Released Lang Actions
Biome secures distribution with Fullscript Canada 4 pages 252.2KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 2 February 2026 about Biome Australia Limited expanding its Canadian practitioner channel through a distribution partnership with Fullscript. It discusses strategic significance, market coverage, and management commentary. There are no financial statements, quarterly or annual results, or detailed financial data. The document is a corporate announcement about a business partnership and market expansion, not a financial report or regulatory filing. It does not fit categories like Annual Report, Interim Report, Earnings Release, or Capital Update. It is a general corporate announcement about business development, best classified under Regulatory Filings (RNS) as a miscellaneous announcement that does not fit other specific categories.
2026-02-01 English
Quarterly Activities & Cashflow Report 14 pages 1.2MB
Interim / Quarterly Report Classification · 100% confidence The document is an ASX announcement dated 27 January 2026, titled 'Quarterly Activities & Appendix 4C December 2025'. It contains detailed quarterly financial highlights including EBITDA, sales revenue, cash position, and cash flow statements. The presence of Appendix 4C, which is a quarterly cash flow report required by ASX Listing Rule 4.7B, confirms this is a quarterly report. The document includes substantive financial data and analysis for the quarter ended 31 December 2025, such as cash flows from operating, investing, and financing activities, and commentary from management. It is not merely an announcement of a report but the report itself with detailed financials. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). Q2 2026
2026-01-26 English
Trading Update 3 pages 296.8KB
Earnings Release Classification · 95% confidence The document is an ASX announcement dated 5 January 2026 providing a trading update for Q2 FY26 and H1 FY26. It reports quarterly and half-year sales revenue figures and growth percentages compared to prior periods. The content focuses on sales performance and forward-looking statements but does not contain detailed financial statements or comprehensive financial analysis typical of an Interim/Quarterly Report. The document is relatively short (5329 characters) and serves as a trading update rather than a full financial report. Therefore, it fits best under the Earnings Release (ER) category, which covers initial announcements of quarterly or periodical financial results with key highlights only. Q2 2026
2026-01-04 English
Biome Launches Human Clinical Trial on BMB18 5 pages 283.3KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 15 December 2025 about Biome Australia Limited launching its first human clinical trial on a proprietary probiotic strain. It details the trial's design, strategic significance, partnership with La Trobe University, and expected outcomes. The content is focused on announcing the initiation and registration of a clinical trial, not on financial results, management changes, or regulatory filings. It does not contain financial statements or detailed financial data. The document is approximately 9,078 characters, which is substantial but the content is clearly an announcement of a clinical trial launch rather than a financial or regulatory report. Therefore, it fits best under the category of a Regulatory Filing (RNS) as a general regulatory announcement that does not fit other specific categories like Annual Report, Earnings Release, or Management Reports.
2025-12-14 English
Biome appoints incoming Chief Financial Officer 5 pages 329.7KB
Board/Management Information Classification · 100% confidence The document is an ASX announcement dated 4 December 2025 about the appointment of a new Chief Financial Officer (CFO) for Biome Australia Limited. It details the background, experience, and qualifications of the incoming CFO, the outgoing CFO's retirement and advisory role, and includes statements from the Managing Director. There is no financial data, no report or financial results, no voting results, no regulatory certifications, or other report types. The document is a management announcement regarding a change in senior management. Therefore, it fits the category of Board/Management Information (MANG). The document length is 7,822 characters, which is sufficient for a detailed announcement but does not contain financial statements or other report content.
2025-12-03 English
Application for quotation of securities - BIO 7 pages 20.6KB
Share Issue/Capital Change Classification · 100% confidence The document is an Appendix 2A form, which is a standard ASX announcement for the application for quotation of securities. It details the issuance and quotation of 2,000,000 ordinary fully paid shares under an employee incentive scheme. The document includes specifics about the securities, issue date, and related approvals but does not contain financial statements or performance data. It is an announcement related to capital changes, specifically the quotation of new securities issued. Therefore, it fits the category of Share Issue/Capital Change (SHA). The document length and content confirm it is not a brief notice but a formal application for quotation, consistent with SHA filings.
2025-12-01 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.